Feasibility Study of Treating Tricuspid Regurgitation With K-ClipTM Transcatheter Annuloplasty System

Tricuspid Regurgitation Clinical Trial

Official title:

Feasibility Study of Treating Tricuspid Regurgitation With K-ClipTM Transcatheter

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05434507
• Other study ID #: HH2021002
• Status: Recruiting
• Phase: N/A
• Start date: September 16, 2021
• Est. completion date: September 16, 2026

Study information

• Verified date: June 2022
• Source: Shanghai Huihe Medical Technology Co., Ltd
• Contact: Sally Yan, project supervisor
• Phone: 18800263183
• Email: Sally.yan[@]hh-healthcare.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the effectiveness and safety of the transcatheter tricuspid annuloplasty system manufactured by Shanghai Huihe Medical Technology Co., Ltd. for the treatment of patients with moderate-severe or worse tricuspid regurgitation

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: September 16, 2026
• Est. primary completion date: September 16, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Aged 60 or older, regardless of gender;

2. Patients with moderate-severe or worse tricuspid regurgitation (TR=3+);

3. The multidisciplinary cardiac team (composed of experts in cardiovascular internal medicine and surgery, imaging, anesthesiology, etc. [No. of experts in cardiovascular surgery >=2]) considers the subjects to be at high risk for surgical operation (STS score > 6.0%) and expects that they will benefit from the transcatheter tricuspid annulus repair;

4. Patient with normal left ventricular function (LVEF=40%);

5. The subject voluntarily participates in the clinical trial and he/she (or his/her guardian) agrees to sign the informed consent form.

Exclusion Criteria:

1. Patients with pulmonary artery systolic pressure =55 mmHg;

2. Patients who have a prosthetic valve or annuloplasty ring at tricuspid valve, or who underwent tricuspid valve-related treatment procedure in the past;

3. Evidence of lumps, thrombus or vegetation in the heart, jugular vein, or superior vena cava;

4. Patients with moderate or worse aortic valve stenosis, mitral stenosis, aortic regurgitation or mitral regurgitation;

5. Patients with severe uncontrolled hypertension (systolic blood pressure =180 mmHg and/or diastolic blood pressure =110 mmHg);

6. Received PCI less than 1 month ago;

7. MI happened or UAP was found less than 1 month ago;

8. CVA occurred less than 3 months ago;

9. Patients with comorbid active endocarditis or active RHD;

10. Patients with coagulation disorder, hypercoagulable state or anemia (HGB < 90 g/L);

11. Patients with acute infection or other severe infections;

12. Patients with active peptic ulcer or active gastrointestinal bleeding;

13. Patients with severe end-stage diseases (e.g., malignant tumors, severe pulmonary diseases, hepatic diseases, renal failure) whose life expectancy is less than 1 year;

14. Patients with known allergies or contraindications to the raw materials of trial product or the drugs (e.g., antiplatelet drugs, anticoagulant drugs);

15. People who are addicted to alcohol, drugs or narcotics;

16. Patients with cognitive impairment who cannot cooperate with the study or follow-up;

17. Those with a history of epilepsy or mental illness;

18. Participated in any other clinical trials (except for registry studies) less than 30 days before the signing the informed consent form;

19. Other situations that the investigator considers inappropriate for participation in this clinical trial.

Related Conditions & MeSH terms

• Tricuspid Regurgitation
• Tricuspid Valve Insufficiency

Intervention

Device:
• Transcatheter Annuloplasty
Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.

Locations

Country	Name	City	State
China	Shanghai Huihe Healthcare Tecnology Co.,Ltd.	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Huihe Medical Technology Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Success rate 1year after operation		1-year after operation
Primary	Success rate of operation		intra-procedure
Primary	Success rate of device implantation		intra-procedure
Primary	Change in echocardiographic parameters	Tricuspid annulus perimeter(mm)	30 days, 6 Months, 12 Months, annual for five years
Primary	Change in echocardiographic parameters	Tricuspid annulus area(mm2)	30 days, 6 Months, 12 Months, annual for five years
Primary	Change of Tricuspid Regurgitation Grade	Number of patients with reduction in TR from baseline	30 days, 6 Months, 12 Months, annual for five years
Primary	NYHA Functional Class	Number of patients with improvement in NYHA class	30 days, 6 Months, 12 Months, annual for five years
Primary	6 minutes walk distance	Increase in distance (m) from baseline	1 month, 6 months,12 Months
Primary	Kansas City Cardiomyopathy Questionnaire	Number of points of improvement in health status as measured by Kansas City Cardiomyopathy Questionnaire	30 days, 6 Months, 12 Months